- Conditions
- Cushing's Syndrome
- Interventions
- osilodrostat
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cushings Disease, Cushing Disease
- Interventions
- LCI699
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 1 more
- Conditions
- Cushing Syndrome
- Interventions
- LCI699
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- San Francisco, California • Cape Coral, Florida • Chicago, Illinois + 2 more
- Conditions
- Mild Autonomous Cortisol Secretion (MACS)
- Interventions
- Osilodrostat (Isturisa)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cushings Disease
- Interventions
- osilodrostat, LCI699 matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 7 more
- Conditions
- Cushing's Disease
- Interventions
- osilodrostat, osilodrostat Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Ann Arbor, Michigan • New York, New York + 2 more
- Conditions
- Hepatic Impairment
- Interventions
- osilodrostat
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Essential Hypertension
- Interventions
- LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Hypertension
- Interventions
- LCI699-matching placebo, LCI699
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Buena Park, California • Harbor City, California + 7 more
- Conditions
- Hypertension
- Interventions
- LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more